Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population
Typical ratios are 27 mg GHK-Cu, 10 mg TB-500, and 5 mg BPC-157, dosed at 0.9-1.8 mg total daily for 6-week cycles
DSIP may provide sleep enhancement without disrupting REM, but clinical data remain insufficient for definitive comparison
Our dedicated team of medical specialists offer a wide variety of healthcare services including preventative care, acute injury care, extensive screening, and medical spa services
10.1007/s00253-024-13049-x 232
Maintenance sessions or oral supplements may be recommended to prolong effects